Compare PRSO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRSO | MDXH |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.0M |
| IPO Year | 2000 | 2021 |
| Metric | PRSO | MDXH |
|---|---|---|
| Price | $0.30 | $0.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $0.83 |
| AVG Volume (30 Days) | ★ 11.7M | 1.3M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,573,000.00 | N/A |
| Revenue This Year | N/A | $1.69 |
| Revenue Next Year | $191.73 | $11.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.28 | $0.11 |
| 52 Week High | $2.10 | $4.34 |
| Indicator | PRSO | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 28.57 |
| Support Level | N/A | N/A |
| Resistance Level | $0.46 | $0.64 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 10.38 | 44.50 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.